Home Your basket
• Guidelines for the clinic...
   Price 12.50 €
• Notes on voice and speech...
   Price 8.50 €
• Orbital decompression in ...
   Price 10.50 €
• Role of positron emission...
   Price 15.00 €
• Reconstruction after tumo...
   Price 10.50 €
• Hygiene and sterilisation...
   Price 10.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Rhinophyma in a black afr...
   Price 5.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• The sound intensity after...
   Price 10.50 €
• Objective analysis of pos...
   Price 8.50 €
• Thyroid differenciated ca...
   Price 10.50 €
• Adenocarcinoma of the end...
   Price 8.50 €
• Toxic nodular goitre asso...
   Price 5.50 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• Improving quality of life...
   Price 12.00 €
• Objective tinnitus and es...
   Price 5.50 €
• Arteriovenous haemangioma...
   Price 8.50 €
• Evaluation of the presenc...
   Price 12.50 €
• Management of cervical ce...
   Price 10.50 €
• Mastoid eosinophilic gran...
   Price 5.50 €
• Cutaneous horn of the pin...
   Price 5.50 €
• The value of fine-needle ...
   Price 10.50 €
• Vestibular-evoked myogeni...
   Price 10.50 €
• Sarcomatoid carcinomas of...
   Price 10.50 €
• Nasal tumours of the thre...
   Price 10.50 €
• An important procedure in...
   Price 8.50 €
• The effectiveness of voic...
   Price 14.00 €
• Peptide receptor radionuc...
   Price 14.00 €
• Papillary thyroid microca...
   Price 10.50 €
• Kikuchi-Fujimoto’s diseas...
   Price 5.50 €

Total Order 290.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2005 o

RHINOLOGY

Treatments of hereditary hemorrhagic telangiectasia of the nasal mucosa


Authors : E. Babin, M. Borsik, S. Braccard, L. Crampette, V. Darrouzet, F. Faure, J. P. Fontanel, E. Houdart, R. Jankowski, G. Le Clech, L. Malvezzi, S. Morini, S. Perie, J. Perret, J. C. Pignat, F. Portier, E. Serrano, H. Plauchu (France - Italie)

Ref. : Rev Laryngol Otol Rhinol. 2005;126,1:43-48.

Article published in french
Downloadable PDF document french



Summary : Hereditary Hemorrhagic Telangiectasia is a systemic autosomal dominant disorder involving blood vessels. The most common symptom is reccurent epistaxis. The treatments of these epistaxis are numerous but such treatments are often symptomatic and their effects are often not sustained. Some of these treatments may be complicated by visceral vascular malformations. The aim of this study is to propose a treatment plan for these patients with hierarchical organisation of therapeutic options taking into account of their previous therapy. Method: H. Plauchu organized in Paris, december 2002 a meeting with any medical specialists of this diesease. They have analysed variety of therapies that have been proposed for epistaxis control in Hereditary Haemorrhagic Télangiectasia. Results: Most common use packing of nasal fossa and then hyperselective embolization of the internal maxillary and facial arteries for severe epistaxis. For chronic epistaxis, best treatment use sclerotics products (Ethibloc®) and laser. After discussion, primary embolization could be useful to reduce vascularization of nasal fossa. Conclusion: Treatment of epistaxis in Hereditary Haemorrhagic Telangiectasia could increase in few years. Use of an index card of for epistaxis in the disease of Rendu-Osler could help to find treatment of choice.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE